Oncology R&D Strategy to Transform Cancer Care – AstraZeneca
3h agoen
From the article
AstraZeneca, shared a post on LinkedIn: “We have a bold ambition in oncology – to one day eliminate cancer as a cause of death. Our Oncology R&D strategy supports our […]
Continue reading on OncoDailyYou might also wanna read
AstraZeneca shares vision of a green and AI-driven future
bioprocessintl.com·1d ago
Molecular glue approach doubles survival time for pancreatic cancer patients in breakthrough trial
Chemical biologist Gregory Verdine developed a novel approach to fighting cancer by using "molecular glues" to bind disease-causing proteins
pasadenastarnews.com·1mo ago
Molecular glue approach doubles survival time for aggressive pancreatic cancer patients
Chemical biologist Gregory Verdine developed a novel approach to fighting cancer by using "molecular glues" to bind disease-causing proteins
pasadenastarnews.com·1mo ago
Experimental once-daily drug doubles survival rates for pancreatic cancer patients
An experimental once-daily drug shows promising results in treating pancreatic cancer, doubling survival rates by slowing disease progressio
to.pbs.org·1mo ago
AI Advances in Drug Discovery: From Data Integration to Dual-Action Cancer Drug Design
The article discusses recent advancements in AI-driven drug discovery, highlighting two key developments: 1) Analytica 2026, an event focuse
drugtargetreview.com·5mo ago
Experimental daraxonrasib pill extends survival for advanced pancreatic cancer patients, study finds
An experimental pill called daraxonrasib has shown promise in helping patients with advanced pancreatic cancer live longer. The drug works b
fox5atlanta.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.